Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment
Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said data from the trial of its SL-401 therapy in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive, lethal malignancy of unmet medical need, with no approved therapies, showed it met its primary endpoint. The trial involved 45 patients and data was presented at this week's American Society of Hematology annual meeting. "The remarkable data presented at ASH from our pivotal trial with SL-401 in BPDCN sets the stage for our upcoming BLA submission and a successful 2018," Stemline Chief Executive Ivan Bergstein said in a statement. Shares have gained 43% in 2017, while the S&P 500 has gained 19%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.